Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000198057 | SCV000253860 | pathogenic | Familial aplasia of the vermis; Meckel-Gruber syndrome | 2024-11-05 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 11 of the CC2D2A gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CC2D2A are known to be pathogenic (PMID: 19777577). This variant is present in population databases (rs200407856, gnomAD 0.04%). Disruption of this splice site has been observed in individual(s) with Joubert syndrome (PMID: 26092869; internal data). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 166801). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
UW Hindbrain Malformation Research Program, |
RCV000201663 | SCV000256347 | pathogenic | Joubert syndrome 9 | 2015-02-23 | criteria provided, single submitter | research | |
Eurofins Ntd Llc |
RCV000597652 | SCV000700659 | pathogenic | not provided | 2017-06-14 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000597652 | SCV002006751 | pathogenic | not provided | 2024-08-06 | criteria provided, single submitter | clinical testing | Canonical splice site variant predicted to result in a null allele in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 29146704, 22848652, 28497568, 26092869, 22241855) |
Fulgent Genetics, |
RCV005031661 | SCV005660516 | likely pathogenic | Meckel syndrome, type 6; Joubert syndrome 9; COACH syndrome 2; Retinitis pigmentosa 93 | 2024-04-09 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004732713 | SCV005361330 | likely pathogenic | CC2D2A-related disorder | 2024-04-30 | no assertion criteria provided | clinical testing | The CC2D2A c.1017+1G>A variant is predicted to disrupt the GT donor site and interfere with normal splicing. This variant has been reported along with a second CC2D2A variant in at least one individual with Joubert syndrome (Supplemental Table S5 in Bachmann-Gagescu et al. 2015. PubMed ID: 26092869). This variant is reported in 0.031% of alleles in individuals of African descent in gnomAD. Variants that disrupt the consensus splice donor site in CC2D2A are expected to be pathogenic. This variant is interpreted as likely pathogenic. |